WINT — Windtree Therapeutics Share News
0.000.00%
Last trade - 00:00Windtree Therapeutics Inc expected to post a loss of $2.27 a share - Earnings Preview
Brief: Windtree Therapeutics Initiates Seismic C Study Of Istaroxime In SCAI Stage C Cardiogenic Shock For Planned Completion Of Phase 2b And Transition To Phase 3
Brief: Windtree Therapeutics Files For $27.2 Mln Stock Sale
Brief: Windtree Announces Expansion Of Patents With Issuance Of Istaroxime Patent For Japan
Brief: Windtree Therapeutics Appoints Jamie Mcandrew As CFO
Brief: Windtree Announces Positive Phase 2B Topline Clinical Results Of Istaroxime
Brief: Windtree Announces Positive Topline Results From Its Phase 2B Seismic Extension Study Of Istaroxime In Early Cardiogenic Shock
Brief: Windtree Therapeutics Positive Topline Results From Phase 2B Seismic Extension Study Of Istaroxime In Early Cardiogenic Shock
Brief: Windtree Completes Enrollment Of Mid-Stage Study Of Istaroxime In Early Cardiogenic Shock
Brief: Windtree Therapeutics Files For Resale Of Up To 10.7 Mln Shares
Brief: Windtree Therapeutics Files For Resale Of Up To 27.7 Million Shares By The Selling Stockholders
Windtree Therapeutics Inc expected to post a loss of $8.11 a share - Earnings Preview
Brief: Windtree Therapeutics Inc On June 26 Co Got Into Common Stock Purchase Agreement With An Equity Line Investor
Brief: Windtree Therapeutics Files For Offering Of Shares Of Common Stock And Accompanying Common Warrants Size Not Disclosed - SEC Filing
Brief: Windtree Therapeutics Regains Compliance With Nasdaq
Brief: Windtree Therapeutics Announces Reverse Stock Split
Windtree Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Windtree Acquires Early-Stage, Novel Oncology Platform, Completes $1.5 Mln Convertible Note Bridge Financing
Brief: Windtree Therapeutics Says It Streamlined Operations, Curtailed Expenses While Seeking Sources Of Capital Through Potential Strategic Transactions